Pharmacokinetic Study of DA-020
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexFemale
Age18-55
SponsorApplied Biology, Inc.
About this trial
Pharmacokinetic Study of DA-020
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Healthy females, age 18-55
BMI: 18-30 kg/m²
Fitzpatrick Skin Types I-IV (to standardize absorption risk)
Scalp free from irritation, dermatologic disease, or damage
Disqualifiers
History of cardiovascular disease, hypertension, or arrhythmia
Scalp infections, wounds, or significant hair loss
Recent use of medications that interfere with CYP enzymes or adrenergic systems
Known sensitivity to phenylephrine or ethanol
Trial design
Design model
Sequential
Treatments tested in this trial
DA-020 (0.1%)
DrugDA-020 (0.1%)
DA-020 (0.2%)
DrugDA-020 (0.2%)
DA-020 (0.5%)
DrugDA-020 (0.5%)
Treatment groups
60 Participants
are divided into 3 treatment groupsGroup A: DA-020 (0.1%)Experimental treatment 1 intervention
Group B: DA-020 (0.2%)Experimental treatment 1 intervention
Group C: DA-020 (0.5%)Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Concentration of DA-020 in Serum
Determine the amount of Oxymetazoline in serum after 1 time scalp application
Time frame
Hours [0, 1, 2, 4, 8, 12, 24]Secondary outcomes
1
Safety and tolerability of DA-020
Determine blood pressure following a single application of DA-020
Time frame
Hours [0, 1, 2, 4, 8, 12, 24]Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Applied Biology, Inc.
Lead sponsor
Daniel Alain, Inc.
Collaborator
Follea International Limited
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: